Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 study of obeticholic acid on clinical outcomes in primary biliary cholangitis
2014-005012-42Phase 4Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Obeticholic acid + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first occurrence of a composite clinical event endpoint. Started Sep 2015; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2014-005012-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005012-42.